![]() |
Name |
Corynesidone A
|
Molecular Formula | C15H12O5 | |
IUPAC Name* |
3,9-dihydroxy-1,7-dimethylbenzo[b][1,4]benzodioxepin-6-one
|
|
SMILES |
CC1=CC(=CC2=C1C(=O)OC3=C(O2)C(=CC(=C3)O)C)O
|
|
InChI |
InChI=1S/C15H12O5/c1-7-3-9(16)5-11-13(7)15(18)20-12-6-10(17)4-8(2)14(12)19-11/h3-6,16-17H,1-2H3
|
|
InChIKey |
KCAVPBLHZJMMLN-UHFFFAOYSA-N
|
|
Synonyms |
Corynesidone A; CHEMBL3221175
|
|
CAS | NA | |
PubChem CID | 42611455 | |
ChEMBL ID | CHEMBL3221175 |
Chemical Classification: |
|
|
---|
Molecular Weight: | 272.25 | ALogp: | 3.0 |
HBD: | 2 | HBA: | 5 |
Rotatable Bonds: | 0 | Lipinski's rule of five: | Accepted |
Polar Surface Area: | 76.0 | Aromatic Rings: | 3 |
Heavy Atoms: | 20 | QED Weighted: | 0.563 |
Caco-2 Permeability: | -5.041 | MDCK Permeability: | 0.00002140 |
Pgp-inhibitor: | 0.006 | Pgp-substrate: | 0.023 |
Human Intestinal Absorption (HIA): | 0.011 | 20% Bioavailability (F20%): | 0.81 |
30% Bioavailability (F30%): | 0.015 |
Blood-Brain-Barrier Penetration (BBB): | 0.147 | Plasma Protein Binding (PPB): | 97.13% |
Volume Distribution (VD): | 0.504 | Fu: | 2.32% |
CYP1A2-inhibitor: | 0.974 | CYP1A2-substrate: | 0.477 |
CYP2C19-inhibitor: | 0.751 | CYP2C19-substrate: | 0.067 |
CYP2C9-inhibitor: | 0.667 | CYP2C9-substrate: | 0.884 |
CYP2D6-inhibitor: | 0.495 | CYP2D6-substrate: | 0.8 |
CYP3A4-inhibitor: | 0.603 | CYP3A4-substrate: | 0.161 |
Clearance (CL): | 13.704 | Half-life (T1/2): | 0.808 |
hERG Blockers: | 0.017 | Human Hepatotoxicity (H-HT): | 0.01 |
Drug-inuced Liver Injury (DILI): | 0.268 | AMES Toxicity: | 0.117 |
Rat Oral Acute Toxicity: | 0.924 | Maximum Recommended Daily Dose: | 0.951 |
Skin Sensitization: | 0.926 | Carcinogencity: | 0.236 |
Eye Corrosion: | 0.038 | Eye Irritation: | 0.963 |
Respiratory Toxicity: | 0.869 |